Patheon Inc

Patheon — Debt Investor Presentation (November 2012)

47 slides from Patheon's debt investor presentation, Nov 13, 2012

  1. Slide 1: Patheon Lender Information

    Patheon Lender Information November 13, 2012 Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements • This presentation contains forward-looking statements or information which reflect Patheon Inc.’s (“Patheon,” the “Company,” “we,” “us,” or “our”) expectations regarding possible events, conditions, our future growth, results of operations, performance, and business pros

  3. Slide 3: Use of Non-GAAP Measures

    Use of Non-GAAP Measures • This presentation includes certain financial measures that have not been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These measures include Adjusted EBITDA, Pro Forma (“PF”) Adjusted EBITDA, PF Adjusted EBITDA less Ma

  4. Slide 4: Financial Information on a GAAP and Non-GAAP Basis

    Financial Information on a GAAP and Non-GAAP Basis US $ millions 2009 2010 2011 2012E Revenue 655.1 671.2 740.9 Gross Profit 144.1 134.4 131.8 157.2 Income (loss) before disc. operations 1.1 (2.9) (15.8) (102.6) Cash provided by operating activities 39.1 50.0 22.9 31.5 Cash used in investing activit

  5. Slide 5: Outline

    Outline • Introductions • Transaction Summary • Executive Summary • Patheon Update • Acquisition Summary • Key Credit Strengths • Historical Financial Review

  6. Slide 6: Patheon

    ¢Patheon Performance tie World Over

  7. Slide 7: Presenters Overview

    Presenters Overview Stuart Grant Executive Vice President, Chief Financial Officer, Patheon James Mullen Chief Executive Officer, Patheon Michael Lytton Executive Vice President, Corporate Development and Strategy, and General Counsel, Patheon

  8. Slide 8: Patheon Leadership

    Patheon Leadership James Mullen CEO Stuart Grant CFO Michael Lytton EVP Corporate Development • Mr. Mullen joined Patheon in 2011 as CEO • Prior to joining Patheon, he served as CEO and President at Biogen Idec Inc. from 2003 to 2010, one of the world's largest biotechnology companies • Mr. Mullen w

  9. Slide 9: Patheon Transformation

    Patheon Transformation • Strong market position and brand • Further strengthened with increased customer focus • $650MM underlying revenue – Excludes one-time contract cancellation benefit of $50MM • Increased PF revenue to approximately $744MM – No single customer more than 11% • $33MM PF Adjusted

  10. Slide 10: Patheon

    ¢Patheon Performance tie World Over

  11. Slide 11: Transaction Summary

    Transaction Summary • On October 29 2012, Patheon, a leading provider of commercial manufacturing and pharmaceutical development services of branded and generic prescription drugs to the international pharmaceutical industry, entered into a definitive agreement to purchase Banner Pharmacaps (the “Ac

  12. Slide 12: Sources & Uses and Pro Forma Capitalization

    Sources & Uses and Pro Forma Capitalization Adjusted Capitalization ($MM) Pro Forma Amount x 10/31/2012 PF Adjusted EBITDA % of Capitalization Net Debt / PF Adj. EBITDA 3.9x Sources ($MM) (%) Uses ($MM) (%) Cash $27.4 Revolver ($85.0) (1) $0.0 0.0x 0.0% Term Loan B $565.0 4.0x 52.3% Short Term & Oth

  13. Slide 13: Patheon

    ¢Patheon Performance tie World Over

  14. Slide 14: Executive Summary

    Executive Summary • Patheon is a leading Contract Development and Manufacturing Organization (“CDMO”) with global reach and long-standing client relationships – In 2011, the Board strengthened the management team with senior leaders from biopharma industry – Management refocused the Company on effic

  15. Slide 15: Patheon

    ¢Patheon Performance tie World Over

  16. Slide 16: Patheon Overview and Global Network

    Patheon Overview Patheon’s Global Network • Market leading CDMO with global footprint in growing industry of pharmaceutical outsourcing • 2012 estimated PF Revenues of $744 million and PF Adjusted EBITDA of approximately $102 million, respectively • Operates in two distinct yet synergistic segments

  17. Slide 17: Two Business Segments Across a Diversified Customer Base

    CMO – $605MM PDS – $139MM Patheon Participates in Two Business Segments Across a Broadly Diversified Customer Base Top 5 CMO clients do not overlap with Top 5 PDS clients CMO and PDS are distinct businesses with PDS originating 25% of CMO business • ~ 5-year contract duration • Size $100K – $50MM+ •

  18. Slide 18: Only Company with Leadership Position in Both CMO and PDS

    Patheon is the Only Company with a Leadership Position in both CMO and PDS Markets CMO PDS $12.3Bn Market Size (1) (+5% Growth Rate) $1.4Bn Market Size (1) (+7% Growth Rate) • Healthy growth (5%) expected in simple oral, but much higher in steriles (10%+) • Patheon is vendor of choice since it can t

  19. Slide 19: Patheon

    oPatheon.

  20. Slide 20: Delivering Against First Two Elements of Strategy

    Patheon has been Delivering against First Two Elements of Strategy since Early 2011 and is now Moving Towards Later Elements Strengthen core operations Sell business differently Enter logical adjacencies Drive industry consolidation • Benchmarking proved Patheon lagged comps in operations (per produ

  21. Slide 21: Operational Transformation Increased Adjusted EBITDA by approx. $40 Million

    2012 Impact ($MM) Operational Transformation is estimated to have increased Adjusted EBITDA by approx. $40 million in Fiscal Year 2012 Achieved Cost Savings & Pricing Initiatives Strengthen core operations 1 2 3 4 5 6 7 Patheon set out to achieve $37MM in Adjusted EBITDA impact in 2012 Global suppor

  22. Slide 22: Selling the Business Differently with Integrated Solutions

    We have also been Selling the Business Differently by Offering Integrated Solutions to Our Customers Sell business differently Solution and “targeted” selling builds on our strengths in PDS and CMO within solids and sterile injectables Recent major multi-year contract win with Boehringer Ingelheim i

  23. Slide 23: Patheon

    ¢Patheon Performance tie World Over

  24. Slide 24: Banner Overview

    Banner Overview Banner Company Overview Banner Customers Proprietary Technology • #2 leading manufacturer of gelatin-based (soft-gel/gelcaps) drug delivery and specialty pharmaceuticals • Owns IP related to 7 different technologies for: – Controlled release (time and target) – Absorption enhancement

  25. Slide 25: Banner Revenues by Geography and Segment

    Current Revenues are Generated Primarily in North America and from a Portfolio of Proprietary Products Sales by Geography (1) Sales by Segment (1) Europe 14% Latin America 16% U.S. + Canada 70% CMO 38% Proprietary Products 62% • Expands Patheon’s presence in US, EU, and parts of Latin America • Path

  26. Slide 26: Acquisition Rationale

    Acquisition Rationale • Increases Size and Scale in attractive CDMO market – Diversifies top line customers and channels – Allows for increase in capacity utilization and efficiency gains • Gives Patheon access to New Customer Segments (end-sellers, buying clubs, and broad range of generics partners

  27. Slide 27: Patheon

    ¢Patheon Performance tie World Over

  28. Slide 28: Summary of Credit Highlights

    Summary of Credit Highlights Increased Diversity of Revenue and Profitability Leading Positions in Large and Attractive Markets Global and Diversified Manufacturing Network Recurring Revenue Model with High Visibility Best in Class Management Team Industry Leading Quality Record

  29. Slide 29: Increased Diversity of Revenue and Profitability

    Increased Diversity of Revenue and Profitability $139MM $167MM $605MM $104MM $709MM $139MM $167MM $320MM $387MM $37MM $190MM $38MM $43MM $577MM $358MM $43MM $37MM CMO 81% PDS 19% CMO 38% Proprietary 62% EUR 43% NA 52% NA 70% EUR 14% LatAm 16% Rest 35% #P1_11% Other 5% Other 4% LatAM 4% Rest 24% Rest

  30. Slide 30: Recurring Revenue Model with High Visibility

    Recurring Revenue Model with High Visibility 92% 6% 27% 73% 20% 80% Under Contract New Sales New Sales Patheon CMO Patheon PDS Banner Under Contract Under Contract New Product Launches Other • PDS business under contract has historically resulted in 2.5x initial revenue over lifetime 2%

  31. Slide 31: Leading Positions in Large and Attractive Markets

    #1 Market Share #2 Market Share Leading Positions in Large and Attractive Markets #2 Market Share 11% 6% 5% 2% 51% 32% 16% 11% 3% 23% 9% 9% 8% 4% 3% 47% $12.3Bn market size (% Market Share) Catalent PF Patheon Strides Accucaps Aenova ProBio Capsugel All Others $1.7Bn market size (% Market Share) Sof

  32. Slide 32: Industry Leading Quality Record

    934 Customer Audits Industry Leading Quality Record • Neither Patheon nor Banner has had any warning letters in last 5 years • 4.2 inspections / audits per week • Nearly 1 in every 3 inspections resulted in zero observations • 19 pre-approval inspections waived • Thorough understanding of worldwide

  33. Slide 33: Global and Diversified Manufacturing Network

    Global and Diversified Manufacturing Network Cincinnati, USA (PDS, CMO solid/sterile) Mexico City, Mexico San Francisco, USA (PDS development) Toronto, Canada (PDS, CMO solids) Alberta, Canada Whitby, Canada (PDS, CMO solids) Swindon, England (PDS, CMO sterile) HQ High Point, NC Bourgoin, France (PD

  34. Slide 34: Best in Class Management Team

    Proven ability to drive value through growing core business, expanding into ancillary markets and integrating complementary acquisitions James Mullen Chief Executive Officer (CEO) Best in Class Management Team Antonella Mancuso Global Commercial Operations and Chief Manufacturing Officer Michael Leh

  35. Slide 35: Historical Financial Review

    Historical Financial Review

  36. Slide 36: Patheon Standalone Historical Financial Performance

    Patheon Standalone Historical Financial Performance PF Revenue ($MM) PF Gross Profit ($MM) % Growth % Margin PF Adjusted EBITDA ($MM) PF Adjusted EBITDA less Maintenance Capex ($MM) % Margin 4.3% 2.5% 6.3% 2012E 22.0% 20.0% 23.3% 19.1% 2012E 2012E 12.9% 12.8% 13.7% 11.9% 2012E Patheon Benefit of con

  37. Slide 37: Combined Historical and Pro Forma Financial Performance

    Combined Historical and Pro Forma Financial Performance Total PF Adj. EBITDA ($MM) Total PF Adj. EBITDA less Maint. Capex ($MM) PF Revenue ($MM) Total PF Gross Profit ($MM) Patheon Banner Run Rate Synergies % Growth % Margin % Margin 1,022

  38. Slide 38: Patheon

    ¢Patheon Performance tie World Over

  39. Slide 39: Summary of Key Terms

    Summary of Key Terms Borrower Guarantors Security Purpose Lead Arrangers and Bookrunners Administrative Agent Facility and Pricing Tranche Amount Maturity Accordion Amortization Optional Redemption Mandatory Repayments Financial Covenants Other Covenants Patheon Inc. Material wholly-owned subsidiari

  40. Slide 40: Pro Forma Organizational Structure

    Pro Forma Organizational Structure Loan parties represent 81% of each of combined revenues and assets Patheon Finance LLC (US) Patheon, Inc. (CAN) Parent Borrower Patheon (UK) Ltd (UK) Subsidiary Borrower Patheon B.V. (NL) Patheon International AG (CH) Patheon International Inc (CAN) Patheon Holding

  41. Slide 41: Summary of Credit Highlights

    Summary of Credit Highlights Increased Diversity of Revenue and Profitability Leading Positions in Large and Attractive Markets Global and Diversified Manufacturing Network Recurring Revenue Model with High Visibility Best in Class Management Team Industry Leading Quality Record

  42. Slide 42: Patheon

    ¢Patheon Performance tie World Over

  43. Slide 43: 2012 Quarterly PF Adjusted and Adjusted EBITDA Bridges

    2012 Quarterly PF Adjusted and Adjusted EBITDA Bridges (unaudited) (1) Represents amortization of stock-based compensation and non-cash foreign exchange gains and losses. (2) Represents consulting fees related to Patheon's operational excellence program recorded in the months ended October 31, 2012.

  44. Slide 44: 2009-2012 Annual PF Adjusted and Adjusted EBITDA Bridges

    2009-2012 Annual PF Adjusted and Adjusted EBITDA Bridges (unaudited) 2012 Est. $ $ $ $ Income (loss) before discontinued operations 1.1 (2.9) (15.8) (102.6) Add (deduct): Provision for (benefit from) income taxes 12.6 (13.8) 1.1 41.9 Loss on sale of capital assets - 0.2 0.2 0.6 Refinancing expenses

  45. Slide 45: Total PF Revenue and Gross Profit Bridges

    Total PF Revenue and Gross Profit Bridges (unaudited) Represents estimated revenue/gross profit for Banner for the months ended October each year. Represents costs related to a recall by one of Patheon’s customers. Represents additional estimated savings/revenue from operational excellence projects

  46. Slide 46: Bridges to Cash Provided by Operating Activities

    Bridges to Cash Provided by Operating Activities (unaudited) 2012 Est Total PF Adjusted EBITDA 139.7 Total maintenance capex Total PF Adjusted EBITDA less maintenance capex 87.9 88.6 Estimated Banner Adjusted EBITDA less maintenance capex (1) 17.5 20.2 17.6 Synergies (2) 12.5 PF Adjusted EBITDA less

  47. Slide 47: Maintenance Capex and Free Cash Flow Bridges

    Maintenance Capex and Free Cash Flow Bridges (unaudited) Maintenance Capex 2012 Est. Maintenance capital expenditures 14.6 21.6 14.3 18.5 Project capital expenditures 34.5 27.1 33.5 32.4 Total Capital expenditures 49.1 48.7 47.8 50.9 Free cash flow 1st half 2nd half 2012 Est. Cash flow (used in) pro

Patheon — Debt Investor Presentation (November 2012) on 6ix